Traced studies on metabolism of astaxanthin in Atlantic salmon (Salmo salar)

Bioaccessibility of Marine Carotenoids

The benefit of carotenoids to human health is undeniable and consequently, their use for this purpose is growing rapidly. Additionally, the nutraceutical properties of carotenoids have attracted attention of the food industry, especially in a new market area, the 'cosmeceuticals.' Marine organisms (microalgae, seaweeds, animals, etc.) are a rich source of carotenoids, with optimal properties for industrial production and biotechnological manipulation. Consequently, several papers have reviewed the analysis, characterization, extraction and determination methods, biological functions and industrial applications. But, now, the bioaccessibility and bioactivity of marine carotenoids has not been focused of any review, although important achievements have been published. The specific and diverse characteristic of the marine matrix determines the bioavailability of carotenoids, some of them unique in the nature. Considering the importance of the bioavailability not just from the health and nutritional point of view but also to the food and pharmaceutical industry, we consider that the present review responds to an actual demand.

Different ratios of docosahexaenoic and eicosapentaenoic acids do not alter growth, nucleic acid and fatty acids of juvenile cobia (Rachycentron canadum)

An experiment was performed to study the effect of different ratios of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on the growth, nucleic acid and fatty acids of cobia (Rachycentron canadum) juveniles. The juveniles were fed for 8 weeks using seven treatment diets (D-1-D-7) with the same amount of DHA and EPA (1.50 +/- 0.1% of dried diet), but varying ratios of DHA to EPA (0.90, 1.10, 1.30, 1.50, 1.70, 1.90, 2.10, respectively) and a control diet (D-0, DHA + EPA = 0.8% of dried diet, DHA/EPA = 1.30). At the end of the experiment, the mean body weight (BW) of juveniles fed D-0-D-7 increased significantly (from 6.86 +/- 1.64 in the week 0 to 58.52 +/- 16.45 g at the end of week 8, P < 0.05). The mean RNA amount and RNA/DNA ratio in the muscle (from 39.62 +/- 1.30 microg mg(-1) and 2.29 +/- 0.11 in the week 0 to 272.55 +/- 10.70 microg mg(-1) and 14.54 +/- 1.75 at the end of week 8, respectively) and the mean weight in the liver (from 117.70 +/- 11.15 microg mg(-1) and 3.14 +/- 0.25 in the week 0 to 793.07 +/- 13.38 microg mg(-1) and 13.16 +/- 0.76 at the end of week 8, respectively) of cobia juveniles fed D-0-D-7 were significantly higher at the end of 8-week experiment than initially (P < 0.05). The RNA/DNA ratio in the muscle and liver of cobia juveniles increased with their growth and appeared an obvious positive relationship, especially in the muscle, based on regression analysis. The mean lipid content increased significantly in the liver (from 29.82 +/- 0.99 to 37.47 +/- 3.25% totally) and muscle (from 6.74 +/- 0.25 to 10.63 +/- 0.23% totally) of cobia juveniles (P < 0.05). However, no significant difference was found on the lipid contents of juveniles fed different diets for 8 weeks (P > 0.05). In the muscle and liver of juveniles, EPA decreased with its reduction in the diet; DHA, DHA/EPA ratio and poly unsaturated fatty acids (PUFAs) generally increased with their increment in the diet. The conclusion was drawn that the growth, nucleic acid and fatty acids of cobia juveniles were not significantly affected by different DHA/EPA ratios in our experiments.

Intraperitoneal and dietary administration of astaxanthin in rainbow trout (Oncorhynchus mykiss) — Plasma uptake and tissue distribution of geometrical E/Z isomers

Astaxanthin enters circulation in salmonid fishes upon intraperitoneal injection (IP) of small doses. Blood uptake and tissue distribution of geometrical E/Z astaxanthin isomers were determined in tissues and plasma of duplicated groups of rainbow trout (Oncorhynchus mykiss, initial weight 550 g) some of which were administered high doses of astaxanthin by IP in a trial lasting for 8 weeks. Doses of 10 (IP10), 50 (IP50) or 100 mg (IP100) astaxanthin (Lucantin Pink, BASF, Germany), respectively, dispersed in phosphate buffered saline were tested in comparison with diets containing 10 (Control) or 60 (Fed 60) mg astaxanthin kg(-1). Astaxanthin concentrations in all examined tissues and plasma were significantly higher in IP50 and IP100 than in controls and Fed 60 (p<0.05). In IP50, 11 mg astaxanthin kg(-1) muscle was detected after 4 weeks, compared to 4 mg kg(-1) in rainbow trout fed 60 mg kg(-1). Concentrations up to 80 and 100 mg astaxanthin kg(-1) were detected in liver and kidney after IP, respectively, whereas fish only fed astaxanthin contained about 2 mg astaxanthin kg(-1). No increase in muscle astaxanthin concentration was found between 4 and 8 weeks in fish given IP, and the muscle astaxanthin concentration in IP50 and IP100 were similar. Muscle concentration and injected dose were curvilinearly correlated and the proportion of ingested dose retained by the muscle was negatively correlated with the amount of injected astaxanthin. Plasma and muscle concentrations of astaxanthin were highly correlated (p<0.0001). Astaxanthin Z-isomers accumulated selectively in the various tissues after IP, whereas all-E-astaxanthin was preferably absorbed into plasma when administered via the diet. There was a selective uptake of all-E-astaxanthin in the muscle of all fish. Mortality was not affected by treatment, but a dose-dependent reduction in SGR was evident after IP. In conclusion, a more rapid and higher uptake of astaxanthin in plasma, muscle, kidney and liver of rainbow trout takes place after IP compared to when astaxanthin is fed via the diet.